Coherus BioSciences, Inc. (CHRS)
| Market Cap | 1.10B |
| Revenue (ttm) | 442.68M |
| Net Income (ttm) | -76.28M |
| Shares Out | 72.83M |
| EPS (ttm) | -1.06 |
| PE Ratio | n/a |
| Forward PE | 32.89 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $14.50 |
| Previous Close | $14.02 |
| Change ($) | 0.48 |
| Change (%) | 3.42% |
| Day's Open | 14.26 |
| Day's Range | 14.10 - 14.50 |
| Day's Volume | 741,971 |
| 52-Week Range | 12.90 - 22.22 |
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab plus chemotherapy for the f...
REDWOOD CITY, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Car...
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Coherus BioSciences (NASDAQ:CHRS) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 97.92% year over year to $0.01, which ...
REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 28, 2021, the compensation committee o...
REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be relea...
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Blade--Blade Therapeutics announces the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer (CFO) effective immediately.
Their recent struggles may soon give way to rising market interest and more lucrative returns.
REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in ...
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with firs...
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHRS vs. ILMN: Which Stock Is the Better Value Option?
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has acc...
Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences Co....
REDWOOD CITY, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation committee ...
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Dir...
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan He...
REDWOOD CITY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee...
REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation committee...
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CHRS vs. ILMN: Which Stock Is the Better Value Option?
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market c...
Coherus develops and markets biosimilar versions of blockbuster biologic products.
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
Coherus BioSciences' (CHRS) CEO Denny Lanfear on Q2 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –
REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effec...
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.
REDWOOD CITY, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after marke...
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
One way to increase the chances of finding high-quality investments is to look for fairly priced stocks of companies that have good financial conditions and are expected to improve their net earnings pe...
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream
Coherus Biosciences: Worth The Risks
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
REDWOOD CITY, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate pri...
REDWOOD CITY, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other condi...
COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimuma... [Read more...]
| Industry Biotechnology | IPO Date Nov 6, 2014 |
| CEO Dennis Lanfear | Employees 310 |
| Stock Exchange NASDAQ | Ticker Symbol CHRS |
Financial Performance
In 2020, CHRS's revenue was $475.82 million, an increase of 33.63% compared to the previous year's $356.07 million. Earnings were $132.24 million, an increase of 47.21%.
Analyst Forecasts
According to 10 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 25.25, which is an increase of 74.14% from the latest price.